GIMEMA ALL - Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia

被引:0
作者
Camera, A
Annino, L
Chiurazzi, F
Fazi, P
Cascavilla, N
Fabbiano, F
Marmont, F
Di Raimondo, F
Recchia, A
Vignetti, M
Rotoli, B
Mandelli, F
机构
[1] Univ Naples Federico II, I-80131 Naples, Italy
[2] Univ Roma La Sapienza, Rome, Italy
[3] Civil Hosp, Pescara, Italy
[4] Ferrarotto Hosp, Catania, Italy
[5] S G Battista Hosp, Turin, Italy
[6] Cervello Hosp, Palermo, Italy
[7] IRCCS, San Giovanni Rotondo, Italy
[8] GIMEMA Data Ctr, Rome, Italy
[9] S Giovanni Hosp, Rome, Italy
关键词
acute lymphoblastic leukemia; relapse; high dose chemotherapy; stem cell transplant;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives. The outcome of adult patients with acute lymphoblastic leukemia (ALL) is discouraging, only about 30% of them becoming long-term survivors. A small fraction of patients are resistant to the first line treatment, while most patients relapse within two years of achieving complete remission (CR). No standard treatment exists for refractory or relapsed patients. The GIMEMA group designed a phase 11 trial for adult ALL patients with refractory or relapsed disease. Design and Methods. Patients aged >15 years with primary refractory or relapsed ALL were eligible for this study. The salvage strategy included a single high dose of idarubicin combined with high dose cytarabine, followed by consolidation therapy leading to a stem cell transplant procedure according to donor availability. Results. From 1998 to 2002, 135 patients were enrolled. Seventy-five patients (55%) achieved CR, including 12 Philadelphia-positive cases; 44 patients had persistent leukemia and 16 died during reinduction. Fifty patients received a stem cell transplant: 19 from an HL-A identical sibling, 16 from an unrelated donor, 7 from a haploidentical relative, 2 received cord blood, and 6 had an autotransplant. The median disease-free and overall survival were both short (5.0 and 6.4 months, respectively); however, after a median follow-up of 40 months, 13 patients are alive, 10 of whom are free of disease (9 transplanted), while 3 are alive with leukemia. Interpretation and Conclusions. The treatment induced CR in a high percentage of poor prognosis patients, thus rendering a transplant procedure feasible in most of them. However, significant rates of transplant-related mortality and post-transplant relapse encourage the search for more effective and less toxic conditioning regimens.
引用
收藏
页码:145 / 153
页数:9
相关论文
共 50 条
  • [31] Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study
    Bhatla, Teena
    Hogan, Laura E.
    Teachey, David T.
    Bautista, Francisco
    Moppett, John
    Puyo, Pablo Velasco
    Micalizzi, Concetta
    Rossig, Claudia
    Shukla, Neerav
    Gilad, Gil
    Locatelli, Franco
    Baruchel, Andre
    Zwaan, C. Michel
    Bezler, Natalie S.
    Rubio-San-Simon, Alba
    Taussig, David C.
    Raetz, Elizabeth A.
    Mao, Zhengwei J.
    Wood, Brent L.
    Arias, Diana Alvarez
    Krevvata, Maria
    Nnane, Ivo
    Bandyopadhyay, Nibedita
    Solano, Lorena Lopez
    Dennis, Robyn M.
    Carson, Robin
    Vora, Ajay
    [J]. BLOOD, 2024, 144 (21) : 2237 - 2247
  • [32] Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Salhotra, Amandeep
    Yang, Dongyun
    Mokhtari, Sally
    Al Malki, Monzr M.
    Ali, Haris
    Sandhu, Karamjeet S.
    Aribi, Ahmed
    Khaled, Samer
    Mei, Matthew
    Budde, Elizabeth
    Snyder, David
    Cao, Thai
    Spielberger, Ricardo
    Marcucci, Guido
    Pullarkat, Vinod
    Forman, Stephen J.
    Nakamura, Ryotaro
    Stein, Anthony
    Aldoss, Ibrahim
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (06) : 1084 - 1090
  • [33] Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia
    Dinner, Shira
    Lee, Daniel
    Liedtke, Michaela
    [J]. LEUKEMIA & LYMPHOMA, 2014, 55 (08) : 1715 - 1724
  • [34] Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia
    George, Binsah
    Kantarjian, Hagop
    Jabbour, Elias
    Jain, Nitin
    [J]. IMMUNOTHERAPY, 2016, 8 (02) : 135 - 143
  • [35] Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia
    Enrico Maffini
    Francesco Saraceni
    Francesco Lanza
    [J]. Clinical Hematology International, 2019, 1 (2) : 85 - 93
  • [36] Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group
    Saito, Takeshi
    Hatta, Yoshihiro
    Hayakawa, Fumihiko
    Takahashi, Tsutomu
    Hagihara, Maki
    Iida, Hiroatsu
    Minauchi, Koichiro
    Yamazaki, Etsuko
    Sugiura, Isamu
    Murayama, Tohru
    Sakura, Toru
    Mori, Naoki
    Imai, Kiyotoshi
    Yahagi, Yuichi
    Atsuta, Yoshiko
    Saito, Akiko Moriya
    Hirakawa, Akihiro
    Kiyoi, Hitoshi
    Matsumura, Itaru
    Miyazaki, Yasushi
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 395 - 403
  • [37] Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party
    Jung, Sung-Hoon
    Lee, Se-ryeon
    Yang, Deok-Hwan
    Lee, Seok
    Yoon, Jae-Ho
    Lee, Hyewon
    Bang, Soo-Mee
    Koh, Youngil
    Park, Silvia
    Kim, Dae Sik
    Yhim, Ho-Young
    Kim, Sung-Hyun
    Lee, Ji-Hyun
    Sohn, Sang Kyun
    Song, Ik-Chan
    Lee, Hong-ghi
    Cheong, Jung-Won
    Choi, Yunsuk
    Shin, Ho-Jin
    [J]. ANNALS OF HEMATOLOGY, 2019, 98 (01) : 151 - 158
  • [38] Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
    Luca Bertamini
    Jacopo Nanni
    Giovanni Marconi
    Mariachiara Abbenante
    Valentina Robustelli
    Francesco Bacci
    Antonella Matti
    Stefania Paolini
    Chiara Sartor
    Silvia Lo Monaco
    Maria Chiara Fontana
    Stefano De Polo
    Michele Cavo
    Antonio Curti
    Giovanni Martinelli
    Cristina Papayannidis
    [J]. BMC Cancer, 18
  • [39] IMPACT OF REINDUCTION REGIMENS FOR RELAPSED AND REFRACTORY ACUTE LYMPHOBLASTIC-LEUKEMIA IN ADULTS
    WELBORN, JL
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 1994, 45 (04) : 341 - 344
  • [40] Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
    Bertamini, Luca
    Nanni, Jacopo
    Marconi, Giovanni
    Abbenante, Mariachiara
    Robustelli, Valentina
    Bacci, Francesco
    Matti, Antonella
    Paolini, Stefania
    Sartor, Chiara
    Lo Monaco, Silvia
    Fontana, Maria Chiara
    De Polo, Stefano
    Cavo, Michele
    Curti, Antonio
    Martinelli, Giovanni
    Papayannidis, Cristina
    [J]. BMC CANCER, 2018, 18